Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.

Article  CAS  PubMed  Google Scholar 

Glatzer M, Leskow P, Caparrotti F, Elicin O, Furrer M, Gambazzi F, et al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. Transl Lung Cancer Res. 2021;10(4):1960–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahvi DA, Liu R, Grinstaff MW, Colson YL, Raut CP. Local Cancer recurrence: the realities, challenges, and opportunities for New therapies. CA Cancer J Clin. 2018;68(6):488–505.

Article  PubMed  PubMed Central  Google Scholar 

Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(1):104–14.

Article  PubMed  Google Scholar 

Hui Z, Men Y, Hu C, Kang J, Sun X, Bi N, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 Non-small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: the phase 3 PORT-C randomized clinical trial. JAMA Oncol. 2021;7(8):1178–85.

Article  PubMed  Google Scholar 

Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. J Thorac Oncol. 2013;8(7):940–6.

Article  PubMed  Google Scholar 

Wang S, Ma Z, Yang X, Wang Y, Xu Y, Xia W, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol. 2017;12(1):207.

Article  PubMed  PubMed Central  Google Scholar 

Zhang C-C, Yu W, Zhang Q, Cai X-W, Feng W, Fu X-L. A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. Radiother Oncol. 2022;173:313–8.

Article  CAS  PubMed  Google Scholar 

Liu J, Ladbury C, Kim J, Raz D, Erhunmwunsee L, West HJ, et al. Postoperative Radiation Therapy should be used for completely resected stage III-N2 NSCLC in select patients. J Thorac Oncol. 2022;17(2):194–6.

Article  PubMed  Google Scholar 

Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The Tumor Microenvironment: a Milieu Hindering and Obstructing Antitumor Immune responses. Front Immunol. 2020;11:940.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G et al. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer. 2022;10(6).

Feng W, Li Y, Shen L, Zhang Q, Cai X-W, Zhu Z-F, et al. Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach. Ther Adv Med Oncol. 2021;13:1758835920984975.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berg TJ, Pietras A. Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells. Semin Cancer Biol. 2022;86(Pt 3):846–56.

Article  CAS  PubMed  Google Scholar 

Hendry S, Salgado R, Gevaert T, Russell P, John J, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology biomarkers Working Group: part 2: TILs in Melanoma, gastrointestinal Tract Carcinomas, Non-small Cell Lung Carcinoma and Mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the Head and Neck, Genitourinary Carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311–35.

Article  PubMed  PubMed Central  Google Scholar 

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.

Article  CAS  PubMed  Google Scholar 

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med. 2012;10:205.

Article  PubMed  PubMed Central  Google Scholar 

Feng W, Li Y, Shen L, Cai X-W, Zhu Z-F, Chang J-H, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. Oncotarget. 2016;7(6):7227–40.

Article  PubMed  PubMed Central  Google Scholar 

Postoperative radiotherapy in. Non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis trialists Group. Lancet. 1998;352(9124):257–63.

Article  Google Scholar 

Kovács A, Stenmark Tullberg A, Werner Rönnerman E, Holmberg E, Hartman L, Sjöström M, et al. Effect of Radiotherapy after breast-conserving surgery depending on the Presence of Tumor-infiltrating lymphocytes: a long-term Follow-Up of the SweBCG91RT Randomized Trial. J Clin Oncol. 2019;37(14):1179–87.

Article  PubMed  Google Scholar 

Kim A, Lee SJ, Ahn J, Park WY, Shin DH, Lee CH, et al. The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma. PLoS ONE. 2019;14(11):e0224430.

Article  CAS  PubMed  PubMed Central  Google Scholar